Assessing the utility of transgenic expression of noncatalytic mutant prostate-specific antigen (PSA/KLK3) or kallikrein 2 (hK2/KLK2) as markers for disease development and progression in different cancersusceptible mouse models
Final Report Abstract
Prostate cancer is the most common cancer diagnosed in men. Prostate specific antigen (PSA) detected in blood is widely used as biomarker for early detection, disease monitoring and treatment efficacy of prostate cancer in daily clinical practice. Abundant expression of proPSA and processing to catalytic, functional PSA is exclusively restricted to the prostate epithelium in men. Levels of PSA released into blood are strongly associated with diagnosis and outcome of prostate cancer. Functional orthologs to PSA are present in dogs and certain primates that are susceptible to spontaneously develop prostate cancer but absent in mice and most other mammals which interestingly do not spontaneously develop prostate cancer. Factors that impact PSA release into blood in a benign or malign setting and its putative pathophysiologic role in influencing prostate diseases remain unknown as prior models failed to establish functional, catalytic PSA. Novel, carefully validated experimental models are needed to further investigate the putative impact of PSA on prostate cancer development and to identify factors which might impact PSA release into blood.
Publications
- Deutsche Gesellschaft für Urologie: Kongress Duesseldorf 2010: Transgenic mice over-expressing functional prostate specific antigen do not develop any macro- or microscopic pathology in the prostate
Christian von Bodman
- European Association of Urology Annual Meeting 2010 Barcelona: Design and validation of novel transgenic model over-expressing catalytic or non-catalytic PSA in the mouse prostate: association with release of PSA into blood
Christian von Bodman
